Get the Stockscreener App
12.18
2.44%
0.29
After Hours:
12.18
Amneal Pharmaceuticals Inc stock is traded at $12.18, with a volume of 2.36M.
It is up +2.44% in the last 24 hours and up +4.19% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$11.89
Open:
$12.01
24h Volume:
2.36M
Relative Volume:
1.38
Market Cap:
$3.83B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-17.90
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-2.72%
1M Performance:
+4.19%
6M Performance:
+69.87%
1Y Performance:
+41.14%
1-Day Range:
$11.90
$12.21
1-Week Range:
$11.71
$12.55
52-Week Range:
$6.685
$12.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.18 | 3.75B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal Pharmaceuticals Reports 'Substantial Clinical Benefit' from Crexont in Phase 4 Study - marketscreener.com
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease - The Manila Times
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Will Amneal Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Amneal wins FDA approval for generic albuterol inhaler - World Aerosols
How Amneal Pharmaceuticals Inc. stock compares to market leaders2025 Top Gainers & Consistent Profit Alerts - Newser
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
AT&T sues generic drugmakers over alleged price-fixing scheme - Reuters
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Canada
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - simplywall.st
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment - geneonline.com
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05% - Ophthalmology Times
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - marketscreener.com
FDA approves Amneal’s generic albuterol inhaler - Investing.com
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - The Manila Times
Amneal to Participate in Upcoming Investor Conferences - The Manila Times
Amneal (Nasdaq: AMRX) adds 2nd Q4 2025 inhaler with FDA approval in $1.5B market - Stock Titan
How institutional buying supports Amneal Pharmaceuticals Inc. stockWeekly Market Summary & Safe Entry Zone Identification - Newser
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - Sahm
Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05% - TipRanks
FDA approves Amneal’s generic Restasis for dry eye disease By Investing.com - Investing.com Australia
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
FDA approves Amneal’s generic Restasis for dry eye disease - Investing.com
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout - marketscreener.com
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies - Quiver Quantitative
Amneal (NASDAQ: AMRX) gets FDA OK for cyclosporine 0.05% eye drug, Q1 2026 launch - Stock Titan
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25% - simplywall.st
Looking at the Narrative for Amneal as Analyst Targets Shift After Recent Milestones - Yahoo Finance
Is Amneal Pharmaceuticals Still an Opportunity After 61% Price Surge in 2025? - Yahoo Finance
Prudential Financial Inc. Sells 65,965 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $625,000 Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Holdings Lowered by Geode Capital Management LLC - MarketBeat
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? - sharewise.com
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? - sharewise.com
Amneal gets FDA nod for Iohexol Injection - MSN
What insider trading reveals about Amneal Pharmaceuticals Inc. stockWeekly Trend Report & Smart Allocation Stock Tips - BỘ NỘI VỤ
Nomura Asset Management Co. Ltd. Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assessing Amneal Pharmaceuticals (AMRX) Valuation Following FDA Approval for Generic Omnipaque Launch in 2026 - Sahm
Amneal Pharmaceuticals stock hits 52-week high at $12.12 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.12 - Investing.com
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Approval of First Generic Omnipaque - Sahm
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs - AOL.com
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know - Finviz
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $586,000.00 in Stock - MarketBeat
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Yahoo Finance
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):